1. Home
  2. HAPN vs MPLT Comparison

HAPN vs MPLT Comparison

Compare HAPN & MPLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Happen Inc. Common Stock

HAPN

Happen Inc. Common Stock

N/A

Current Price

$14.97

Market Cap

1.7B

Sector

Finance

ML Signal

N/A

Logo MapLight Therapeutics Inc.

MPLT

MapLight Therapeutics Inc.

HOLD

Current Price

$10.23

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HAPN
MPLT
Founded
N/A
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.7B
IPO Year
2008
2025

Fundamental Metrics

Financial Performance
Metric
HAPN
MPLT
Price
$14.97
$10.23
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
★ $32.67
AVG Volume (30 Days)
★ 1.1M
444.4K
Earning Date
N/A
05-28-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 157.78
82.39
EPS
★ 0.94
N/A
Revenue
★ $314,702,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$15.85
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$14.61
$9.10
52 Week High
$21.25
$40.43

Technical Indicators

Market Signals
Indicator
HAPN
MPLT
Relative Strength Index (RSI) 25.43 28.32
Support Level N/A $9.10
Resistance Level $21.25 $14.22
Average True Range (ATR) 0.45 0.73
MACD -0.09 0.06
Stochastic Oscillator 14.17 2.49

Price Performance

Historical Comparison
HAPN
MPLT

About HAPN Happen Inc. Common Stock

Happen Inc is a U.S. digital marketplace bank focused on the Motivated Middle - high FICO, high-income borrowers actively managing their financial lives. The bank's success is fueled by evolved credit underwriting, a proprietary technology platform, and a marketplace bank model that generates compelling revenue through loan sales, net interest income, and fee-based services.

About MPLT MapLight Therapeutics Inc.

MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.

Share on Social Networks: